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Abstract
Introduction: Hypoxia in solid tumors is associated with treatment resistance, resulting in poor prognosis. Tribbles
homolog 3 (TRIB3) is induced during hypoxia and is involved in multiple cellular pathways involved in cell survival.
Here, we investigated the role of TRIB3 in breast cancer.
Methods: TRIB3 mRNA expression was measured in breast tumor tissue from 247 patients and correlated with
clinicopathological parameters and clinical outcome. Furthermore, we studied TRIB3 expression regulation in cell
lines, xenografts tissues and human breast cancer material using Reverse transcriptase, quantitative polymerase
chain reaction (RT-qPCR) and immunohistochemical staining. Finally, the effect of small interfering RNA (siRNA)
mediated TRIB3 knockdown on hypoxia tolerance was assessed.
Results: Breast cancer patients with low, intermediate or high TRIB3 expression exhibited a mean disease free
survival (DFS) of 80 (95% confidence interval [CI] = 74 to 86), 74 (CI = 67 to 81), and 63 (CI = 55 to 71) months
respectively (P = .002, Mantel-Cox log-rank). The prognostic value of TRIB3 was limited to those patients that had
received radiotherapy as part of their primary treatment (n = 179, P = .005) and remained statistically significant
after correction for other clinicopathological parameters (DFS, Hazard Ratio = 1.90, CI = 1.17 to 3.08, P = .009). In
breast cell lines TRIB3 expression was induced by hypoxia, nutrient starvation, and endoplasmic reticulum stress in
an hypoxia inducible factor 1 (HIF-1) independent manner. TRIB3 induction after hypoxia did not increase with
decreasing oxygen levels. In breast tumor xenografts and human breast cancer tissues TRIB3 co-localized with the
hypoxic cell marker pimonidazole. The induction of TRIB3 by hypoxia was shown to be regulated via the PERK/
ATF4/CHOP pathway of the unfolded protein response and knockdown of TRIB3 resulted in a dose-dependent
increase in hypoxia sensitivity.
Conclusions: TRIB3 is independently associated with poor prognosis of breast cancer patients, possibly through its
association with tumor cell hypoxia.
Introduction
The accelerated growth and erratic angiogenesis of solid
tumors induce a lack of oxygen and nutrients in parts of
the tumor that are distal to functional blood vessels.
This is known to have important repercussions for treat-
ment sensitivity and prognosis of cancer patients [1-3].
Variation in the duration and severity of hypoxic stress
differentially activates different “do or die” programs
and leads to substantial phenotypic variations amongst
otherwise identical tumor cells. Best known in this per-
spective is the Hypoxia-Inducible Factor 1 (HIF-1) path-
way, which is induced during hypoxia and has often
been associated with poor prognosis in solid tumors
including breast cancer [4-6]. Under more anoxic condi-
tions another hypoxia-related program is activated, that
is the unfolded protein response (UPR) [7], which
results from endoplasmic reticulum (ER) stress caused
by misfolding of proteins in the ER. One of the
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mechanisms that are activated by the UPR is autophagy
[8], which can temporarily relieve ER stress by reutiliza-
tion of cellular components. ER stress-induced expres-
sion of activating transcription factor 4 (ATF4) and
CHOP (C/EBP homologous protein) also leads to tran-
scription of Tribbles homolog 3 (TRIB3) [9]. TRIB3 is
known to inhibit phosphorylation of AKT/protein kinase
B (AKT) [10]. AKT is a phosphoinositide-dependent
serine/threonine protein kinase that plays a critical role
in the signal transduction of growth factor receptors.
Furthermore, TRIB3 has been described to have a role
in the mitogen activated protein kinase (MAPK) path-
way [11] and nuclear factor (NF) B activated apoptosis
[7]. However, the literature is not conclusive on the role
of TRIB3 in cell fate; it has been described to have pro-
apoptotic [9] as well as anti-apoptotic features [12].
TRIB3 is strongly upregulated by hypoxia, nutrient star-
vation and ER stress-inducing agents [13-15] and has
been implicated in ER stress-induced autophagy [16].
Interestingly, TRIB3 was shown to be upregulated com-
pared with normal tissue in tumors of the human lung,
colon, and breast [14,17,18].
We hypothesized that TRIB3 could be relevant for
breast cancer prognosis, because in breast cancer, sev-
eral ER stress, UPR, and/or hypoxia-associated markers
have been found to be related to prognosis [19-22].
Furthermore, the involvement of TRIB3 in the other
pathways described above makes it more interesting
than other proteins in the UPR and other hypoxia path-
ways, because, for example, the growth factor receptor-
induced phosphorylation cascades are also known to be
relevant for breast cancer treatment [23]. We hypothe-
sized that TRIB3 could be an important protein by
determining the tumor cell fate under stressed condi-
tions. To this end, TRIB3 mRNA expression levels were
correlated with disease characteristics and patient survi-
val in a large breast cancer patient cohort. In addition,
we determined if TRIB3 expression could be induced in
breast cancer cells by a variety of stressors, and we
assessed the expression and localization of TRIB3 in
breast cancer xenografts and patient tissues. Finally, we
determined the effect of TRIB3 knockdown on the
hypoxia response of breast cancer cells.
Materials and methods
Patient samples
Coded tumor tissues were used in accordance with the
Code of Conduct of the Federation of Medical Scientific
Societies in the Netherlands (’Code for Proper Second-
ary Use of Human Tissue in the Netherlands’ [24]). The
study adhered to all relevant institutional and national
guidelines, and was reported according to REMARK
guidelines [25]. A series of 247 patients with unilateral,
resectable breast cancer who had undergone resection
of their primary tumor between November 1987 and
December 1997 were selected based on the availability
of frozen tissue in the tumor bank of the Department of
Laboratory Medicine of the Radboud University Nijme-
gen Medical Centre. This bank contains frozen tumor
tissue from breast cancer patients of seven different hos-
pitals of the Comprehensive Cancer Centre East in the
Netherlands. The patients, inclusion and exclusion cri-
teria, and their treatment have been described earlier
[26]. To summarize, the median age was 59 years (range
31 to 88 years). Patients had undergone modified radical
mastectomy (n = 178) or a breast-conserving lumpect-
omy (n = 69). Postoperative radiotherapy to the breast
after an incomplete resection or after breast-conserving
treatment, or parasternal radiotherapy when the tumor
was medially localized, had been administered to 179
patients. Adjuvant systemic therapies were given almost
exclusively to the 128 patients with lymph node involve-
ment, according to standard practice at that time [26].
During follow up, 95 patients experienced a recurrence,
either local or distant. A representative part of each
tumor was macroscopically selected by a pathologist.
The material was frozen in liquid nitrogen and determi-
nation of estrogen receptor and progesterone receptor
status was performed by ligand binding assay according
to the dextran-charcoal method [27]. Aliquots of tissue
were pulverized using a microdismembrator (Braun,
Melsungen, Germany) and kept in liquid nitrogen until
RNA isolation.
To obtain patient material containing the exogenous
hypoxia marker pimonidazole, patients with newly
diagnosed breast cancer were enrolled in the period
1997 to 1999 in a tumor hypoxia study in accordance
with a research protocol approved by the Institutional
Review Board at the University of North Carolina Hos-
pitals. The patients provided signed informed consent
prior to their participation in the study. Prior to tumor
biopsy, patients received an intravenous infusion of
pimonidazole hydrochloride (0.5 g/m2, Hypoxyprobe-
1™, NPI Inc, Belmont, MA, USA) diluted in 100 ml
NaCl 0.9% for 20 minutes. Between 16 to 24 hours
later, biopsies were obtained from primary tumors.
After biopsy, fresh tumor samples were placed in cold
10% neutral buffered formalin, held at 4°C for 12 to 24
hours, and processed into paraffin blocks. Four μm
thick sections were sectioned and mounted on glass
slides in preparation for immunohistochemical stain-
ing. One slide per block was stained with hematoxylin
and eosin for pathologic review to confirm the pre-
sence of tumor. Based on the hypoxia scoring of the
tumors according to a calibrated scoring system [28]
three tumors with a high percentage of hypoxia (> 15%
of the viable area) were chosen for analysis of TRIB3
expression.
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Xenograft tissue
Xenografts of MDA-MB-231 cells were obtained after
subcutaneous injection of 1 × 106 cells suspended in
RPMI (MP Biomedicals, Illkirch, France) in six-week-old
female athymic mice (BALB/c nu/nu, BonholdGard,
Denmark). Animal housing and experimental procedures
were in accordance with international guidelines and
approved by the local ethical committee for animal use,
respectively. At a mean tumor diameter of 6 to 8 mm at
approximately six weeks after seeding that time mice
were injected intravenously with 0.1 ml of 0.9% NaCl
containing 2 mg of the hypoxic cell marker pimonida-
zole hydrochloride (1-((2-hydroxy-3-piperidinyl)propyl)-
2-nitroimidazole hydrochloride, Natural Pharmaceuti-
cals, Inc., Research Triangle Park, NC, USA) 60 minutes
before harvesting the tumors. Pimonidazole is a biore-
ductive chemical probe with an immuno-recognizable
side chain, which was described previously as a marker
for hypoxia [29-31]. The animals were killed by cervical
dislocation and the harvested xenograft tissues were
immediately frozen in liquid nitrogen.
Cell lines
MCF7 and MDA-MB-231 (ATCC, LGC Promochem,
London, UK) human breast cancer cells were cultured
for a limited number of passages in standard culture
medium ((DMEM, MP Biomedicals, Amsterdam, the
Netherlands) with 10% dialyzed FCS (Invitrogen, Breda,
the Netherlands), 2 mM L-glutamine, 20 mM HEPES, 10
U/ml penicillin, 10 μg/ml streptomycin, and nonessential
amino acids (NEAA, MP Biomedicals)) at 37°C with 5%
CO2, unless stated otherwise. Knockdown of TRIB3 was
performed using siRNA transfection reagent SAINT-RED
(Synvolux Therapeutics BV, Groningen, the Nether-
lands). siRNAs MISSION® siRNA Universal Negative
Control #1 (SIC001), TRIB3 (1) (SASI_Hs01_00197510)
and TRIB3 (2) (SASI_Hs01_00197511) were acquired
from Sigma-Aldrich (St. Louis, MO, USA). The knock-
down of HIF-1a, PRKR-like endoplasmic reticulum
kinase (PERK), inositol-requiring 1 (IRE1), activating
transcription factor 6 (ATF6), ATF4 and CHOP was per-
formed in MCF7 cells as described previously for
HCT116 cells [32].
Detection of RNA
Total RNA was isolated with the RNeasy RNA isolation
kit (Qiagen, Hilden, Germany) with on-column DNAse
treatment. For the reverse transcriptase quantitative
PCR (RT-qPCR) Reverse Transcription System from
Promega Benelux B.V. (Leiden, the Netherlands) was
used and cDNAs were amplified with specific primers
(TRIB3 forward: att agg cag ggt ctg tcc tgt g, reverse:
agt atg gac ctg gga ttg tgg a; VEGF forward: ccg cag acg
tgt aaa tgt tcc t, reverse:cgg ctt gtc aca tct gca agt a;
PAI-1 forward:ggc cat gga aca agg atg aga, reverse:gac
cag ctt cag atc ccg ct; CAIX forward:gag gcc tgg ccg tgt
tg, reverse:aat cgc tga gga agg ctc ag; MIF forward:cag
ccc gga cag ggt cta c, reverse:tct tag gcg aag gtg gag ttg;
ATF4 forward: cct tca cct tct tac aac c, reverse: gta gtc
tgg ctt cct atc t; GRP78/BiP forward:tct atg aag gtg aaa
gac cc, reverse:ctg tca ctc gaa gaa tac ca) using Sybr
Green Master Mix (Applied Biosystems, Nieuwerkerk a/
d lJssel, the Netherlands) on an ABI Prism 7700
Sequence detection system (Applied Biosystems, Nieu-
werkerk a/d lJssel, the Netherlands). All samples were
normalized for levels of hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) expression. In the experi-
ment in which the pathways involved in TRIB3
regulation were determined, RNA was reverse-tran-
scribed using I-Script (Bio-Rad Laboratories BV, Vee-
nendaal, the Netherlands). Furthermore, these samples
were normalized to 18S rRNA.
Detection of protein
Protein localization of TRIB3 and other relevant pro-
teins or markers in xenograft and human breast cancer
tissue was determined using immunohistochemical
staining. The frozen xenografts or frozen tumor tissues
were sectioned at 5 μm thickness after embedding in
Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, the
Netherlands). Sections were mounted on poly-L-Lysine
coated microscopic slides (Menzel, Braunschweig, Ger-
many), fixated in acetone and rehydrated in 0.1 M phos-
phate buffered saline pH 7.4 (PBS, Klinipath, Duiven,
the Netherlands). Between all antibody incubations, sec-
tions were rinsed three times in PBS (Klinipath, Duiven,
the Netherlands). The following primary antibodies were
dissolved in primary antibody diluent (PAD, AbD sero-
tec, Oxford, UK) and stained with the appropriate
labeled secondary antibodies; rabbit-anti-TRIB3 (Calbio-
chem, San Diego, CA, USA), PAL-E for blood vessels in
human tissue (Euro Diagnostica, Arnhem, the Nether-
lands), rat monoclonal against mouse endothelium (9F1,
kind gift from Dr. G. van Muijen of the Department of
Pathology, Radboud University Nijmegen Medical Cen-
tre, Nijmegen, the Netherlands), and rabbit-anti-pimoni-
dazole for hypoxic regions in xenograft tissue. Slides
were enclosed using Fluorostab (ICN pharmaceuticals,
Inc. Zoetermeer, the Netherlands). Paraffin embedded
breast tissue sections (4 μm) were deparaffinized and re-
hydrated in histosafe (Klinipath, Duiven, the Nether-
lands) and graded alcohols (100%-96%-70%). For antigen
retrieval, slides were heated (90°C) in 10 mM citrate
buffer pH 6.0 (DAKO, Glostrup, Denmark). Endogenous
peroxidase was blocked with 3% H2O2 in methanol
before the incubation with polyclonal rabbit-anti-TRIB3
(Novus Biologicals, Cambridge, UK) or rabbit-anti-pimo-
nidazole. Subsequently, slides were incubated with
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Powervision (Lab Vision Products, Thermo Fisher Scien-
tific, Cheshire, UK) and visualization of peroxidase was
performed using PowerDAB (Lab Vision Products,
Thermo Fisher Scientific, Cheshire, UK). A counterstain
with hematoxylin (Klinipath, Duiven, the Netherlands)
was performed before dehydration and mounting using
Permount (Thermo Fisher Scientific, Cheshire, UK).
All microscopic images were acquired using IP-Lab for
Macintosh software (Scanalytics Inc., Fairfax, VA, USA)
in combination with a monochrome CCD camera
(Retiga SRV, 1392 × 1040 pixels) and a RGB filter (Sli-
der Module; QImaging, Burnaby, BC, Canada) attached
to a motorized microscope (Leica DM 6000, Wetzlar,
Germany). For comparison between TRIB3 and pimoni-
dazole expression, whole tumor sections were scanned
with a 10× objective at 100× magnification [33]. The
individual colors (DAB (brown) and hematoxylin (blue)
signals) were extracted and unmixed from the bright
fields images [33].
Treatment of cells
For anoxia experiments, treatments included addition of
1.2 U/ml oxyrase (Oxyrase, Inc., Mansfield, OH, USA), a
reagent that removes all oxygen from culture medium
[34,35] or 100 μM CoCl2 (Sigma, Zwijndrecht, the Neth-
erlands), a hypoxia mimetic, to the standard culture
medium. The effect of CoCl2 on HIF-1a protein levels
stabilization was confirmed by performing a standard
western blot analysis [36] with minor adjustments using
mouse anti-HIF-1a (BD Biosciences, Erembodegem, Bel-
gium) antibody and the effect on HIF-1 activity by mea-
suring CAIX expression on mRNA level.
For less than 0.01% O2 exposure, MCF7 cells were
transferred to a hypoxic culture chamber (MACS
VA500 microaerophilic workstation, Don Whitley Scien-
tific, West Yorkshire, UK) as described previously [32].
For 0.1% to 0.5% O2 exposure MDA-MB-231 cells were
transferred to a hypoxic culture chamber (H35 hypoxys-
tation, Don Whitley Scientific, West Yorkshire, UK).
In nutrient starvation experiments, either glucose-free
DMEM including the same additions as the standard cul-
ture medium, or the standard culture medium in which
the NEAA were omitted, were used. To induce ER-stress,
0.5 μM thapsigargin (Sigma, Zwijndrecht, the Netherlands)
was added to the standard culture medium.
Cell proliferation assay
To measure cell survival we used the CellTiter 96®
AQueous One Solution Cell Proliferation Assay (MTS,
Promega Benelux BV, Leiden, the Netherlands). Assays
were performed in a 96-well plate format in which cells
were transfected with siRNA 24 hours after seeding.
Treatment started 24 hours after transfection. Directly
after treatment for 48 hours 20 μl of MTS solution was
added to 100 μl cell culture medium per well. After
three hours of incubation with MTS absorbance at 492
nm was measured using a Multiskan Ascent Photo-
metric plate reader (Labsytems, Helsinki, Finland).
Statistical analyses
Statistical analyses were carried out using SPSS 10.0.5 soft-
ware (SPSS Benelux BV, Gorinchem, the Netherlands).
Normality of distribution of variables was tested using
Kolmogorov-Smirnov testing. Differences in TRIB3
expression in cells with different treatments were evalu-
ated using analysis of variance (ANOVA) and post-hoc
Tukey’s testing. Differences in levels of TRIB3 expression
in samples from patients categorized by clinicopathologi-
cal characteristics, used as grouping variables, were
assessed with non-parametric Mann-Whitney U tests (for
two groups) or with Kruskall-Wallis tests (for more than
two groups) where appropriate. Non-parametric correla-
tions were established using Spearman Rank correlation
testing. Disease free survival (DFS) time (defined as the
time from surgery until diagnosis of recurrent or meta-
static disease) and overall survival (OS) time (defined as
the time between date of surgery and death by any cause)
were used as follow-up endpoints. Survival curves were
generated using the method of Kaplan and Meier, after
patients were categorized by TRIB3 expression in either
two or three equally sized groups, thus either at the p50,
or at the p33 and p66. Equality of survival distributions
was tested using log-rank testing, with Mantel-Cox test for
trend when more than two groups were analyzed, and
using Cox univariate and multivariable regression analyses.
Variables were selected for the multivariable survival ana-
lyses by backward stepwise selection, with removal testing
based on the probability of the likelihood-ratio statistic, at
a P > 0.10. Two-sided P-values below 0.05 were considered
to be statistically significant. Cases with more than 96
months of follow up were censored at 96 months, because
of the rapidly declining number of patients thereafter,
although data on some patients was available for up to 169
months after primary surgery. This censoring was done
because after a certain period of observation patients are
frequently redirected to their general practitioner for
checkups and mammography and cease to be among the
outpatients of the breast cancer clinics. Further inclusion
of the small remaining groups in statistical analyses would
be non-informative. Additionally, the data met the propor-
tional hazard assumption, and hazard ratios did not
change over time.
Results
TRIB3 mRNA association with a poor prognosis in human
breast cancer
To investigate whether the variation in TRIB3 expres-
sion is relevant for prognosis in breast cancer, TRIB3
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mRNA levels were measured in 247 tumor samples
from breast cancer patients. The TRIB3 levels were log-
normally distributed among the patient samples, with 26
of 247 (10.5%) samples in which TRIB3 levels were not
detectable. TRIB3 levels showed no association with
most clinicopathological characteristics (Table 1). TRIB3
mRNA levels were only significantly different in tumors
that were not of ductal or lobular histology.
When the patients were divided into three equally sized
groups based on the level of TRIB3 mRNA in the primary
tumor the group with the lowest amount of TRIB3 expres-
sion had a mean DFS of 80 months (95% confidence inter-
val (CI) = 74 to 86 months), whereas the group with an
average amount of TRIB3 had a mean DFS of 74 months
(95% CI = 67 to 81 months) and the group with high levels
of TRIB3 had a mean DFS of 63 months (95% CI = 55 to
71 months; P = 0.002, Figure 1a). Patients with the lowest
amount of TRIB3 expression had a mean OS of 91 months
(95% CI = 88 to 94 months), whereas those with an inter-
mediate amount of TRIB3 had a mean OS of 83 months
(95% CI = 77 to 89 months) and those with high levels of
TRIB3 had a mean OS of 74 months (95% CI = 67 to 80
months; P < 0.001, Figure 1b). Similar differences were
found after division of the patients in two equal groups
(DFS: hazard ratio (HR) = 2.15, 95% CI = 1.39 to 3.31, P <
0.001; OS: HR = 3.48, 95% CI = 2.00 to 6.06, P < 0.001;
Table 2), and when TRIB3 was entered as a continuous
factor after log-normalization in a univariate Cox regres-
sion analysis (not shown). In multivariate Cox regression
analyses, TRIB3 remained statistically significantly asso-
ciated with both DFS and OS after correction for other
clinicopathological parameters (Table 2).
In exploratory subgroup analyses, we found that the
prognostic value of TRIB3 mRNA expression was lim-
ited to those patients receiving radiotherapy as part of
their primary treatment. In those patients that had a
Table 1 Associations of TRIB3 expression levels with clinicopathological factors
Variable n = 247a Median
(*10-3 TRIB3/HPRT)
Interquartile range
(*10-3 TRIB3/HPRT)
P
Age (years)
< 50 58 8.6 36
≥50 189 6.6 26 0.456b
Menopausal status
Premenopausal 65 9.4 34
Postmenopausal 182 6.6 27 0.500b
Nodal category
Negative 100 9.0 31
< 4 nodes 79 4.7 18
≥4 nodes 39 16 46 0.057c
Tumor type
Ductal 146 8.6 35
Lobular 28 13 25
Other (mixed/unknown) 73 2.7 18 0.007c
Tumor size
pT1 61 5.2 28
pT2 135 7.1 34
pT3/4 47 6.9 22 0.616c
Histological grade
I 11 5.1 17
II 70 6.4 36
III 88 8.5 31 0.729c
Estrogen receptor (fmol/mg protein)
< 10 84 7.2 30
≥10 159 5.8 27 0.895b
Progestrone receptor (fmol/mg protein)
< 10 103 7.1 32
≥10 141 6.6 23 0.663b
aDue to missing values, numbers do not always add up to 247.
b P for Mann-Whitney U test.
c P for Kruskal-Wallis test.
HPRT, hypoxanthine-guanine phosphoribosyltransferase;
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AC
TRIB3 <33% 82 73 63 52 41
TRIB3 33-66% 82 65 54 37 21
TRIB3 >66% 83 56 40 18 13
P = .002
B
P = .719 P = .005
P < .001
Patients at risk
TRIB3 <33% 82 79 69 61 49
TRIB3 33-66% 82 72 64 44 25
TRIB3 >66% 83 67 55 28 17
Patients at risk
D
TRIB3 <33% 20 17 15 12 8
TRIB3 33-66% 25 19 16 7 5
TRIB3 >66% 22 15 11 5 3
TRIB3 <33% 62 56 48 40 33
TRIB3 33-66% 56 46 38 30 16
TRIB3 >66% 61 41 29 13 10
Patients at risk Patients at risk
Disease free survival n = 274 Overall survival n = 274
Disease free survival  
patients without radiotherapy n = 
67
Disease free survival  
patients with radiotherapy n = 179
TRIB3 mRNA levels <33% 33-66% >66%
Figure 1 TRIB3 expression is associated with poor prognosis in breast cancer. Patients where divided into three groups based on their
TRIB3 mRNA levels; less than 33% (dotted line), 33% to 66% (dashed line) and more than 66% (solid line). Kaplan-Meier plots of (a) disease-free
survival (DFS; P = 0.002) and (b) overall survival (OS; P < 0.001) in breast cancer patients (n = 274) and DFS (c) in patients with mastectomy
without further radiotherapy (n = 67, P = 0.719) and (d) in patients that received postoperative radiotherapy (n = 179, P = 0.005).
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mastectomy without further radiotherapy, no relation
between TRIB3 and DFS was seen (P = 0.719, n = 67,
Figure 1c). Postoperative radiotherapy was given to 179
patients (to the breast after an incomplete resection or
after breast-conserving treatment, or parasternal radio-
therapy when the tumor was medially localized). In this
group, TRIB3 was highly significantly associated with
DFS (P = 0.005, n = 179, Figure 1d). We did not find a
correlation between TRIB3 mRNA expression and local/
regional or distant control in the radiotherapy treated
group (P = 0.13, P = 0.11 and P = 0.17 respectively),
neither in the group not treated with radiotherapy (P =
0.91 P = 0.75 and P = 0.84, respectively).
TRIB3 mRNA is induced by a variety of stresses
To test the effect of different stresses on TRIB3 mRNA
expression we used the estrogen receptor positive MCF7
and estrogen receptor negative MDA-MB-231 breast cancer
cells. Anoxia exposure was performed using oxyrase, HIF-1
protein was stabilized using CoCl2, ER stress was induced
by treating the cells with 0.5 μM thapsigargin (an inhibitor
of endoplasmic reticular Ca2+-ATPase), and nutrient starva-
tion was achieved by deprivation of the medium from either
glucose or NEAA. After different incubation periods TRIB3
mRNA levels were measured by RT-qPCR. Figure 2a shows
the results of 24 hours of incubation. TRIB3 expression was
increased in breast cancer cells after 24 hours of anoxia (P
< 0.05, Figure 2a). However, incubation with CoCl2, which
indeed stabilized HIF1a protein confirmed by western blot
(see insert in Figure 2a) and induced HIF1-dependent tran-
scription measured by CAIX mRNA expression (fold induc-
tion ranging from 1.3 to 4.3 for MDA-MB-231 and 35.7 to
65.4 for MCF7 cells) did not induce TRIB3 mRNA. Thapsi-
gargin induced a significant increase in TRIB3 mRNA levels
within two hours, which was further extended after up to
24 hours of incubation (P < 0.01, Figure 2a). After MCF7
cells were starved for glucose for 24 hours, TRIB3 expres-
sion was significantly increased (P < 0.01, Figure 2a). After
omission of NEAA from the growth medium, a statistically
significant increase in TRIB3 mRNA was detected at 48
hours (P < 0.01, data not shown).
TRIB3 induction by hypoxia in breast cancer cells,
xenografts and breast cancer tissues
To specify the oxygen dependence of TRIB3 up-regula-
tion MDA-MB-231 cells were cultured under controlled
Table 2 Cox uni- and multivariate analyses of disease-free survival (DFS) and overall survival (OS) in all patients
(n = 247)
DFS OS
Factor Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
P-value HR (95% CI)a P-value HR (95% CI)a P-value HR (95% CI)a P-value HR (95% CI)a
Age (years) 0.036 0.008 0.939
41-55 vs. ≤40 0.59 (0.30-1.17) 0.38 (0.18-0.79) 1.10 (0.44-2.76)
56-70 vs. ≤40 0.58 (0.31-1.12) 0.53 (0.27-1.06) 0.93 (0.38-2.28)
> 70 vs. ≤40 0.30 (0.13-0.69) 0.20 (0.07-0.55) 0.89 (0.33-2.41)
Menopausal status 0.024 0.255
Post- vs. premenopausal 0.77 (0.61-0.96) 0.73 (0.42-1.25)
Tumor size 0.006 0.023 0.111
pT2 vs. pT1 2.15 (1.17-3.95) 2.36 (1.20-4.65) 1.59 (0.82-3.07)
pT3+4 vs. pT1 2.81 (1.40-5.62) 2.87 (1.30-6.37) 2.23 (1.04-4.77)
Histological grade 0.091 0.768
II vs. I 1.54 (0.36-6.58) 1.38 (0.32-5.94)
III vs. I 2.80 (0.68-11.6) 1.76 (0.42-7.44)
Number of involved lymph nodes 0.001 0.013 0.005 0.006
1-3 vs. node-negative 1.51 (0.89-2.56) 1.41 (0.81-2.44) 1.39 (0.73-2.65) 1.53 (0.80-2.93)
≥4 vs. node-negative 3.29 (1.84-5.88) 2.63 (1.38-5.00) 3.32 (1.67-6.64) 3.17 (1.56-6.43)
Estrogen receptor statusb 0.245 0.845
Positive vs. negative 0.77 (0.50-1.19) 0.95 (0.55-1.63)
Progestrone receptor statusb 0.431 0.650
Positive vs. negative 0.84 (0.55-1.29) 0.89 (0.53-1.48)
TRIB3 < 0.001 0.009 < 0.001 < 0.001
Higher vs. lower than median 2.15 (1.39-3.31) 1.90 (1.17-3.08) 3.48 (2.00-6.06) 3.90 (2.06-7.37)
a Hazard ratio (95% confidence interval (CI))
b positive defined as > 10 fmol/mg protein
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Figure 2 TRIB3 is induced by cell stress and is expressed in hypoxic areas. (a) Fold induction of TRIB3 mRNA expression (mean + standard
deviation (SD)) after 24 hours incubation with hypoxia mimetic (CoCl2, inhibitor of the degradation of HIF-1, see insert), anoxia (oxyrase),
estrogen receptor (ER) stress (thapsigargin) or nutrient starvation in the ER positive MCF7 and the ER negative MDA-MB-231 cell lines. Each
measurement was performed at least in triplicate. (b) Fold induction of TRIB3 mRNA expression (mean + SD) after incubation of MDA-MB-231
cells at increasing oxygen concentrations (oxyrase (~0%), 0.1%, 0.2% and 0.5% oxygen) compared with normoxia. Each measurement was
performed at least in triplicate. (c) Triple fluorescent staining in two different xenografts of MDA-MB-231 cells for TRIB3 (red), pimonidazole
(green), and 9F1 (blue) showing colocalization of TRB3 and hypoxia, distal from blood vessels.
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oxygen concentrations of 0.1, 0.2, and 0.5%. A time
dependent up-regulation of TRIB3 mRNA compared
with HPRT was seen at all tested oxygen tensions after
24 hours. More severe oxygen deprivation does not lead
to a higher induction of TRIB3 compared with inter-
mediate hypoxia (Figure 2b).
Next, to assess whether the oxygen dependence of
TRIB3 expression could also be observed in tissues, fro-
zen sections of MDA-MB-231 human breast cancer cell
xenografts grown on nude mice were triple stained with
fluorescent anti-pimonidazole, anti-TRIB3, and anti-
endothelial antibodies. TRIB3 staining was specifically
seen in the hypoxic regions of the tumor, distant from
the blood vessels (Figure 2c).
Next, we assessed TRIB3 staining in breast cancer tis-
sue from three patients that had received pimonidazole
prior to biopsy. In all three tumor tissues, large pimoni-
dazole positive hypoxic areas were found, often around
necrotic cores. TRIB3 was almost exclusively expressed
in these hypoxic areas (Figure 3). Excellent co-localiza-
tion was seen between pimonidazole and TRIB3 within
the same regions at higher magnification (Figures 3c to
3e). Thus, in human breast cancer tissues, TRIB3 is up-
regulated in hypoxic regions of the tumor, similar to
that seen in xenograft samples shown above.
TRIB3 is induced through the unfolded protein response
via PERK, ATF4 and CHOP
Tumor cells respond to oxygen deprivation by, among
others, stabilization of HIF-1 and activation of the UPR,
which consists of three parallel pathways (PERK, IRE1,
and ATF6) [8,37]. To assess through which of these
pathways TRIB3 is up-regulated after anoxia, TRIB3
mRNA levels were measured in MCF7 cells in which
the different pathways were silenced by gene knockdown
[32]. For all genes used an efficient knockdown for that
specific gene was seen (Figure 4a). In the control cells,
TRIB3 mRNA was strongly induced after culturing
under anoxic conditions (< 0.01% O2; Figure 4b).
Knockdown of HIF-1a did not alter the anoxia induc-
tion of TRIB3 expression at any time point, which is in
line with our results in breast cancer cells after CoCl2
incubation. ATF6 or IRE1 knockdown also did not have
an effect on the anoxia-induced up-regulation of TRIB3.
In contrast, knockdown of PERK, ATF4 or CHOP com-
pletely inhibited the up-regulation of TRIB3 (P < 0.01).
TRIB3 mRNA expression is not a hypoxia marker
Expression levels of other hypoxia and UPR-associated
genes were also determined in the breast cancer patient
cohort. No correlation between TRIB3 mRNA expres-
sion and the hypoxia markers VEGF, PAI-1, CAIX, or
MIF was observed (Spearman correlation coefficient (Rs)
= 0.19, P = 0.05, Rs = -0.38, P = 0.59, Rs = 0.78, P =
0.25 and Rs = 0.11, P = 0.08, respectively). The expres-
sion of ATF4, the main regulator of TRIB3, was border-
line significantly correlated with TRIB3 mRNA
expression (P = 0.05) with a low correlation coefficient
of 0.18. Another UPR-associated gene GRP78/BiP was
not correlated with TRIB3 expression (Rs = 0.12, P =
0.15).
Knockdown of TRIB3 results in a increased hypoxia
sensitivity
MDA-MB-231 cells were used for siRNA-mediated
knockdown of TRIB3. Two different siRNAs against
TRIB3 were used and TRIB3 expression was compared
with cells transfected with negative control siRNA.
TRIB3 (1) siRNA led to a reduction in TRIB3 expression
of 48%, and TRIB3 (2) siRNA led to a reduction of 87%
(Figure 5a). Next, we sought to establish whether TRIB3
is associated with poor prognosis solely as a marker for
hypoxia, or that it has a functional role in hypoxia resis-
tance of tumor cells. To this end, MDA-MB-231 cells
were transfected with the above mentioned TRIB3 siR-
NAs and cultured under normoxic and hypoxic condi-
tions. In cells transfected with control siRNA, the total
activity of cells measured by MTS assay cultured for 48
hours at 0.1% did not differ significantly from cells cul-
tured in standard conditions (Figure 5b). In cells trans-
fected with the two different siRNAs against TRIB3 the
MTS assay readout was significantly (P = 0.003 and P <
0.001 for siRNA TRIB3 (1) and (2), respectively) dimin-
ished after hypoxia. Noteworthy, the siRNA that has the
greatest knockdown effect on TRIB3 mRNA levels also
had the greatest effect on total cell activity after hypoxia.
Discussion
Here, we find that TRIB3 is associated with poor prog-
nosis of breast cancer patients, independent of other
clinicopathological characteristics. TRIB3 is expressed in
hypoxic areas of both breast cancer xenografts and
human breast tumor tissues. We found that this TRIB3
up-regulation is induced by ER stress, hypoxia and
nutrient starvation, and is dependent on the PERK path-
way of the UPR. TRIB3 induction is most pronounced
at a moderate oxygen concentration and TRIB3 seems
involved in hypoxia response of tumor cells.
Tribbles was originally identified as a delayer of mito-
sis in Drosophila Melanogaster [38-40]. One of the three
human homologs, TRIB3, has recently been described to
be involved in regulation of the cell cycle regulator
cdc25A in human cells [41]. Furthermore, TRIB3 has a
role in insulin sensitivity and diabetes [10,42-44] and
has also been described to interact as a scaffold protein
in multiple signaling cascades, including v-akt murine
thymoma viral oncogene homolog 1 (PKB/Akt) [10,13]
but also MAPK [11] pathways. This apparent
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involvement of TRIB3 in tumor cell proliferation and/or
survival and growth factor receptor signaling cascades
combined with its role in hypoxia and cell stress path-
ways [9,13-15,45,46] originally spurred us to investigate
its role in breast cancer progression. Our results pre-
sented here show that TRIB3 could be involved in the
hypoxia response of breast cancer cells; it is induced by
cell stressors including hypoxia, ER stress, and nutrient
starvation in breast cancer cells, which is in line with
earlier observations in other cell types [9,13-15,45,46].
We confirmed here that TRIB3 is part of the UPR
[9,12], more specifically the PERK/ATF4/CHOP path-
way. We find that knockdown of TRIB3 results in cells
that are more sensitive to hypoxia. One pathway
involved in hypoxia tolerance of tumor cells is the UPR
[32]. Tumor cells utilize this pathway to counter cell
stresses like hypoxia, most likely through induction of
autophagy [32]. By “self-eating” of cellular components,
cells can provide for their own energy and constituents,
thereby surviving prolonged periods of severe hypoxia
[32]. TRIB3 is known to inhibit PKB/Akt [10], a putative
link between the UPR and autophagy [16].
Importantly, hypoxic cells are particularly refractory to
treatment and tend to have an increased metastatic
potential [1,3]. Further, the hypoxia and nutrient starva-
tion-induced UPR-pathway is important for cancer
treatment efficacy [21,32,47,48] and therefore an inter-
esting new target for therapy. In comparison with HIF-
1, which is activated over a wide range of oxygen con-
centrations of around 2%, maximum activation of the
UPR requires exposure to more severe hypoxia
(reviewed in [49]). Nevertheless, activation of the UPR
A B
C D E
1mm 1mm
200μm 200μm 200μm
Pimonidazole TRIB3
pimonidazole TRIB3 hematoxylin
Figure 3 TRIB3 colocalizes with pimonidazole in human breast cancer tissue. Results after linear unmixing of scanned images from
immunohistochemical stainings of (a) TRIB3 (DAB, brown) and (b) pimonidazole (DAB, brown), and single images from immunohistochemical
stainings at 100× magnification of (c) TRIB3 (DAB, brown), (d) pimonidazole (DAB, brown) and (e) hematoxylin (blue), in human breast cancer
tissue. See methods for details of unmixing and scanning.
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has been shown to protect tumor cells against hypoxia-
induced cell death both in vitro and in vivo over a range
of oxygen concentrations [47,48,50]. We are the first to
describe the specific oxygen tensions that induce TRIB3,
and found that up-regulation of TRIB3 does not increase
with decreasing oxygen tensions. These results indicate
that the up-regulation of TRIB3 under moderate hypoxia
is at least partly due to other pathways than the UPR.
PI3K is already described to up-regulate TRIB3 expres-
sion [13] and could be responsible for the up-regulation
of TRIB3 at the more physiological moderate hypoxia,
rather than at severe hypoxia (i.e. anoxia). Severe
hypoxia is mainly found in perinecrotic areas within
solid tumors and probably has less influence on
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Figure 4 TRIB3 is induced through the PERK/ATF4/CHOP pathway of the unfolded protein response. (a) mRNA abundance of the specific
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prognosis and treatment sensitivity than areas with more
moderate hypoxia. Within the moderate hypoxic tumor
regions cells can adapt, and are eventually more likely
to reoxygenate and/or metastasize as they are more
proximal to blood vessels.
Here, we show that TRIB3 expression can indepen-
dently predict disease outcome in human breast cancer
patients. The importance of TRIB3 in cancer is sup-
ported by the finding that TRIB3 is also involved in the
prognosis of colorectal cancer patients [17]. The data
suggest that TRIB3 is induced by hypoxia in an ATF4
dependent manner and supports hypoxia sensitivity, but
from the measurements of other hypoxia markers we
find that TRIB3 mRNA abundance from tumor biopsies
is not merely a reflection of tumor hypoxia. This sug-
gests that TRIB3 marks or supports tumor aggressive-
ness rather than reflecting hypoxia itself. Furthermore,
the predictive value of TRIB3 expression in our study
was specifically significant in the patient group that
received radiotherapy. Combined with the observation
that TRIB3 is mostly expressed in the therapy resistant
hypoxic areas of breast tumors this indicates that the
prognostic role of TRIB3 could indeed be a consequence
of therapy resistance. When this would be solely due to
radiotherapy resistance one would expect also a correla-
tion with loco-regional control but this was not the
case. However, a correlation with distant control could
also not be found, probably both due to low number of
events and small group sizes. In addition, as this was a
non-randomized retrospective analysis, any predictive
value of TRIB3 mRNA remains to be confirmed in a lar-
ger prospective trial.
Conclusions
Examining TRIB3 expression in human breast tumor
material revealed that there was an independent associa-
tion with poor prognosis of breast cancer patients. A
relation of TRIB3 with hypoxia was seen by the co-loca-
lization with the hypoxia marker pimonidazole in both
breast cancer xenografts and human breast tumor tissue.
We found that TRIB3 up-regulation after hypoxia, ER
stress and nutrient starvation also holds true for breast
cancer cells and is HIF-1 independent and UPR depen-
dent. TRIB3 up-regulation after hypoxia was found to be
most pronounced at physiological intermediate hypoxia,
in contrast to most UPR-induced proteins. Finally,
knockdown of TRIB3 revealed an effect on hypoxia
response of breast cancer cells. In combination these
results indicate that TRIB3 might be associated with
tumor cell survival under prolonged intermediate
hypoxic stress. This hypothesis warrants further experi-
ments in other (breast cancer) cell lines applying addi-
tional knockdown, possibly with rescue, and/or
overexpression techniques. Furthermore, the
involvement of TRIB3 in multiple important signaling
pathways makes it an interesting target for cancer ther-
apy. Further research will provide more insight into the
mechanisms of action and possibilities of intervention.
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